Open Access
Review
Table 2
Summary of metabolomics studies conducted in animal models of AD.
| Animal model | Sample | Platform | Findings | Ref. |
|---|---|---|---|---|
| APPTg2576(n = 9) WT(n = 10) |
Frontal cortex | NMR | ↑Taurine; ↓N-acetyl-aspartate, glutamate, glutathione |
(Dedeoglu et al., 2004) |
| APPxPS1(n = 7–8) WT(n = 5–9) |
Whole brain | NMR | ↑Myo-inositol, choline, glycerophosphocholine; ↓succinate |
(Forster et al., 2012) |
| CRND8 (n = 5/5 young/old) WT (n = 4/8 young/old) |
Cortex, frontal cortex, cerebellum, hippocampus, striatum, pons, midbrain, olfactory bulb | NMR | ↑Lactate, aspartate, glycine, alanine, leucine, isoleucine, valine, free fatty acids; ↓N-acetyl-aspartate, glutamate, glutamine, taurine, γ-aminobutyric acid, choline, phosphocholine, creatine, phosphocreatine, succinate |
(Salek et al., 2010) |
| APP × PS1(n = 10) WT(n = 10) |
Cortex(frontal, occipital, parietal, temporal), thalamus, hippocampus | NMR | ↑Myo-inositol, scyllo-inositol; ↓N-acetyl-aspartate |
(Woo et al., 2010) |
| APPTg2576(n = 39) WT(n = 44) |
Frontal cortex, rhinal cortex, hippocampus, cerebellum, midbrain | NMR | ↑Creatine, taurine; ↓glutamate, N-acetyl-aspartate, myo-inositol, phosphocholine, γ-aminobutyric acid |
(Lalande et al., 2014) |
| APP × PS1(n = 6) WT(n = 6) |
Whole brain | NMR | ↓N-acetyl-aspartata, γ-aminobutyric acid, creatine, ascorbic acid | (Graham et al., 2013b) |
| APP × PS1(n = 6) WT(n = 6) |
Plasma | NMR | ↓Glutamate, glutamine, methionine, acetate, citrate | (Graham et al., 2013b) |
| APP × PS1(n = 27) WT(n = 33) |
Plasma | NMR | ↑Lipoproteins, triglycerides | (Wu et al., 2016) |
| APP × PS1(n = 27) WT(n = 33) |
Liver | NMR | ↑Unsaturated fatty acids, 3-hydroxybutyrate, aspartate, glutamine, uridine diphosphate, uridine monophosphate, adenosine monophosphate; ↓alanine, lactate, betaine | (Wu et al., 2016) |
| SAMP8(n = 5) SAMR1(n = 5) |
Serum | NMR | ↑Lactate, saturated fatty acids, alanine, methionine, glutamine, VLDL; ↓inosine, glucose, polyunsaturated fatty acids, choline, phosphocholine, HDL, LDL, 3-hydroxy-butyrate, citrate, pyruvate |
(Liang et al., 2008) |
| APPTg2576(n = 3–5) WT(n = 3–5) |
Urine | NMR | ↑3-hydroxykynurenine, homogentisate, allantoin, acetate, trans-aconitate, tyrosine, hippurate, citrate, urea; ↓trigonelline, 2-oxoglutarate, dimethylamine, trimethylamine, threonine, 1-methylnicotinamide |
(Fukuhara et al., 2013) |
| APPV717F, APPV717F × APOE APPsw APPsw × APOE WT |
Cortex, cerebellum | MS | ↓Sulfatides | (Cheng et al., 2010) |
| APP × PS1(n = 30) WT(n = 30) |
Serum | MS | ↑SFA-PLs, eicosanoids, triglycerides, diglycerides, choline, GPE, inosine; ↓PUFA-PLs, LPLs, cholesteryl esters, free fatty acids, urea, serine, valine, threonine, pyroglutamate, creatine, phosphoethanolamine, histidine, carnitine, glucose, tyrosine, tryptophan |
(Gonzalez-Dominguez et al., 2015c) |
| APP × PS1(n = 30) WT(n = 30) |
Hippocampus, cortex, cerebellum, olfactory bulb | MS | ↑LPLs, PL(18:0/20:4), 22:5PLs, 22:4-PLs, propionyl-carnitine, free fatty acids, eicosanoids, uracil, hypoxanthine, xanthine, FAPy-adenine, adenosine, inosine, acetate, propionate, pyruvate, alanine, choline, valine, G3P, phosphocholine, N-acetyl-spermidine, GPC, GPI; ↓PUFA-PLs, acyl-carnitines, steroids, adenine, UMP, AMP, urea, aspartate, dopamine, tyrosine, homocarnosine |
(Gonzalez-Dominguez et al., 2015h) |
| APP × PS1(n = 30) WT(n = 30) |
Liver, kidney, spleen, thymus | MS | Alterations in the metabolism of phospholipids, fatty acids, acyl-carnitines, eicosanoids, acyl-glycerols, steroids, amino acids, nucleotides, energy-related metabolites(changes depending on the tissue) | (Gonzalez-Dominguez et al., 2015e) |
| APP × PS1(n = 8–9) WT(n = 8–9) |
Brain, plasma | MS | Longitudinal perturbations(6–18 months) in metabolism of phospholipids, amino acids, polyamines and acyl-carnitines | (Pan et al., 2016) |
| APP × PS1 × IL4 (n = 7) APP × PS1(n = 7) WT(n = 7) |
Serum | MS | ↓Urea, histamine, threonine, aspartate, urocanic acid, dopamine, citrulline, tyrosine; ↑1-methyl-histamine, eicosanoids |
(Gonzalez-Dominguez et al., 2015g) |
| CRND8(n = 6) WT(n = 6) |
Hippocampus | MS | Alterations in the homeostasis of arachidonic acid, glucose metabolism and fatty acid β-oxidation | (Lin et al., 2013) |
| CRND8(n = 6) WT(n = 6) |
Cerebellum | MS | ↑Eicosanoids, amino acids and derivatives, xanthosine, xanthine, urate; ↓inosine, guanosine |
(Lin et al., 2014) |
| SAMP8 n = 5 (2 months) n = 6 (7 months) n = 7 (12 months) |
Hippocampus | GC-MS | ↑Cholesterol, oleic acid, phosphoglyceride, N-acetyl-aspartate; ↓alanine, serine, glycine, aspartate, glutamate, γ-aminobutyric acid, malic acid, butanedioic acid, fumaric acid, citric acid, pyroglutamic acid, urea, lactic acid |
(Wang HL et al., 2014) |
| TASTPM(n = 16) WT(n = 5) |
Whole brain | GC-MS | ↑D-fructose, valine, serine, threonine; ↑zymosterol |
(Hu et al., 2012) |
| TASTPM(n = 16) WT(n = 5) |
Plasma | GC-MS | ↑D-glucose, d-galactose, linoleica cid, arachidonic acid, palmitic acid, gluconic acid | (Hu et al., 2012) |
| APPTg2576(n = 15) WT(n = 17); CRND8(n = 9) WT(n = 9); APPV717I(n = 10) WT(n = 12) |
Urine | GC-MS | ↑Phenylacetone; ↓3-methylcyclopentanone, 4-methyl-6-hepten-3-one, 6-hydroxy-6-methyl-3-heptanone |
(Kimball et al., 2016b) |
| CRND8(n = 12) WT(n = 12) |
Urine | RP-MS | ↑Methionine, desaminotyrosine, phenylacetylglycine, dihydrouracil, ureidopropionic acid, thiocysteine; ↓choline, taurine, N1-acetyl-spermidine, 5-hydroxy-indoleacetic acid, hydroxyphenylglycine |
(Peng et al., 2014) |
| CRND8 (n = 18/12,12/18 weeks) WT(n = 12/12, 12/18 weeks) |
Urine | HILIC-MS | Fifty-five differential metabolites involved in the homeostasis of amino acids(e.g. tryptophan, tyrosine, phenylalanine, lysine), fatty acids, purines and pyrimidines, ascorbate, and others | (Tang et al., 2016) |
| APP × PS1(n = 30) WT(n = 30) |
Serum | RP-MS/ GC-MS |
Alterations in the metabolism of phospholipids, sphingolipids, fatty acids, cholesterol and bile acids, energy-related metabolites and amino acids | (Gonzalez-Dominguez et al., 2015d) |
| APP × PS1(n = 30) WT(n = 30) |
Hippocampus, cortex, striatum, cerebellum, olfactory bulb | RP-MS/ GC-MS |
Alterations in the metabolism of phospholipids, sphingolipids, energy-related metabolites, amino acids and nucleotides | (Gonzalez-Dominguez et al., 2014d) |
| APP × PS1(n = 30) WT(n = 30) |
Liver, kidney | RP-MS/ GC-MS |
Alterations in the metabolism of phospholipids, sphingolipids, fatty acids, acyl-carnitines, cholesterol and bile acids, energy-related metabolites and amino acids | (Gonzalez-Dominguez et al., 2015f) |
| APP × PS1(n = 30) WT(n = 30) |
Spleen, thymus | RP-MS/ GC-MS |
Alterations in the metabolism of phospholipids, sphingolipids, fatty acids, acyl-carnitines, energy-related metabolites, amino acids and purines | (Gonzalez-Dominguez et al., 2015i) |
| APPTg2576(n = 3) PS1(n = 3) APP × PS1(n = 6) WT(n = 6) |
Hippocampus | RP-MS/ GC-MS |
Alterations in nucleotide, TCA cycle, energy transfer, carbohydrate, neurotransmitter and amino acid metabolic pathways | (Trushina et al., 2012) |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.